Effect of F2695 on Functional Recovery After Ischemic Stroke
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 532 participants.
Also called NCT01639014
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 532 participants
- Sponsor
- Pierre Fabre Medicament
- Registry
-
NCT01639014 -
2012-001592-37
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Belgium, Czechia, France, Germany, Hungary, Italy, Portugal, Russia, Spain, Sweden, Switzerland
- Registry status
- Completed
Technical summary
Registry record NCT01639014. Randomized; quadruple masking; primary purpose treatment. Start 2012-07 (registry gives no type); primary completion 2015-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of F2695 on Functional Recovery After Ischemic Stroke
- Acronym
- LIFE
- Condition
- Ischemic Stroke
- Intervention (Drug)
- F2695
- Intervention (Drug)
- placebo
- Lead sponsor
- Pierre Fabre Medicament
Record details
- Record id
cardio:ct-nct01639014- Content hash
6a3dd3c6086072c7a612391d345b6be30cd27f4ca625f8dc508898c8adef0fa4